Spontaneous Coronary Reperfusion in STEMI After Pre-Hospital Loading Dose of Triple Antithrombotic Therapy.
Clinical Cardiology · 2026-07-01 · Observational study
Abstract
BACKGROUND: To evaluate the incidence and prognosis of spontaneous coronary reperfusion in STEMI using pre-hospital loading dose of P2Y12 inhibitors. METHODS: This prospective bi-centric study included STEMI patients who referred for primary PCI from June 1, to November 1, 2022. All patients received before hospital admission loading dose of aspirin, heparin and P2Y12 inhibitor. The primary outcome was incidence of spontaneous coronary reperfusion (TIMI 3 flow) before primary PCI. Major in-hospital and 1-year events were secondary outcomes. RESULTS: Within the study period, 263 patients were admitted with ongoing STEMI and 49 of them (18.6%) had spontaneous coronary reperfusion with no significant difference between loading dose of ticagrelor (n = 226; 85.9%) or clopidogrel (n = 27, 10.3%) and TIMI 3 flow (n = 41; 18.1% vs. n = 7; 25.9%, p = 0.53; respectively). Peak of T-hs troponin (p < 0.001) and CRP (p = 0.03) were significantly lower in the TIMI 3 group. In multivariate analysis, out-of- hospital cardiac arrests were observed twice as often in the TIMI 3 group (16.33 vs. 7.01%; p = 0.044). There was no significant difference between the two groups regarding major in-hospital (p = 0.69) or 1-year major events (p = 0.20). CONCLUSION: Spontaneous reperfusion at admission was observed in about 20% of STEMI patients who received a pre-hospital loading dose of antithrombotic therapy including P2Y12 inhibitors, and was associated with markers of decrease of infarct size. The significant increase of pre-admission cardiac arrests observed in the TIMI 3 group could be specifically explored as it might be a concern regarding future pre-hospital reperfusion therapy strategies.
Abstract © the authors or publisher, via PubMed. Reuse and removal
Tags
Antithrombotics & thrombolytics · Acetylsalicylic acid · Heparin · Mortality & survival · P2Y12 inhibitors
Related articles
- Effect of early, pre-hospital initiation of high bolus dose tirofiban in patients with ST-segment elevation myocardial infarction on short- and long-term clinical outcome. (J Am Coll Cardiol, 2010)
- Facilitated reperfusion with prehospital glycoprotein IIb/IIIa inhibition: predictors of complete ST-segment resolution before primary percutaneous coronary intervention in the On-TIME 2 trial: correlates of reperfusion before primary PCI. (J Electrocardiol, 2011)
- Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial. (Am Heart J, 2007)
- Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel. (J Am Coll Cardiol, 2007)
- [Acute non ST-elevation coronary syndrome in real practice of hospitals in Russia. Comparative data from RECORD 2 and RECORD registries]. (Kardiologiia, 2012)
- Reperfusion strategies in ST-elevation myocardial infarction--current status and perspectives for early and pre-hospital treatment. (Resuscitation, 2008)